As more therapeutic companies develop gene therapies targeting not only rare diseases, aiming to make these treatments effective and accessible for as many patients as possible, efficient gene editing tools and delivery methods are essential in this development.
Read more about it in the Forbes article featuring Caszyme CEO Monika Paulė: https://www.forbes.com/sites/juergeneckhardt/2024/05/16/how-gene-editing-therapies-could-go-beyond-rare-diseases/